Alector (ALEC) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on therapies for neurodegenerative diseases, targeting high unmet medical needs.

• Develops product candidates using targeted mechanisms such as removing pathogenic proteins, replacing deficient proteins, and restoring cellular function.

• Proprietary Alector Brain Carrier (ABC) platform enhances blood-brain barrier delivery for antibodies, enzymes, and siRNA therapeutics.

• Portfolio includes a Phase 2-ready antibody for Alzheimer's (nivisnebart) and preclinical programs for Alzheimer's, Parkinson's, and Lewy body dementia.

• Invests in biomarker development to guide patient selection and improve clinical development efficiency.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as described in future prospectus supplements, with broad discretion retained for allocation.

• Pending use, proceeds may be invested in short- and intermediate-term investment grade instruments or U.S. government obligations.

Risk factors and disclosures

• Investment involves high risk; risks are detailed in the prospectus, supplements, and incorporated SEC filings.

• Risks include clinical, regulatory, financial, and operational uncertainties, as well as market and economic conditions.

• Forward-looking statements are subject to significant uncertainties and actual results may differ materially.